NCT05173987 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05173987
Title	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme Corp.
Indications	uterine carcinosarcoma endometrial carcinoma
Therapies	Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| SWE \| POL \| NZL \| NOR \| NLD \| ITA \| ISR \| IRL \| HUN \| GBR \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS

Additional content available in CKB BOOST